{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:01:50Z","timestamp":1792760510152,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40257-026-01049-8","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T14:02:23Z","timestamp":1781532143000},"page":"909-923","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A Systematic Review of the Clinical Impact of GLP-1 Receptor Agonists in Hidradenitis Suppurativa"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7349-7459","authenticated-orcid":false,"given":"Maria-Alexandra","family":"Visan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7087-1070","authenticated-orcid":false,"given":"Emma","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6989-4593","authenticated-orcid":false,"given":"Stephanie-Lynn","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1763-3173","authenticated-orcid":false,"given":"Emily","family":"Pender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5906-8654","authenticated-orcid":false,"given":"Daniel-Octavian","family":"Costache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4530-7965","authenticated-orcid":false,"given":"Constantin","family":"Caruntu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6533-0412","authenticated-orcid":false,"given":"Rosalind","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7596-892X","authenticated-orcid":false,"given":"Brian","family":"Kirby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"issue":"5","key":"1049_CR1","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1111\/ijd.17108","volume":"63","author":"Y Gu","year":"2024","unstructured":"Gu Y, Sebaratnam DF. GLP-1 receptor agonists for hidradenitis suppurativa: navigating benefits, risks, and ethical considerations. Int J Dermatol. 2024;63(5):e100\u20131. https:\/\/doi.org\/10.1111\/ijd.17108.","journal-title":"Int J Dermatol"},{"issue":"12","key":"1049_CR2","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1111\/jdv.20694","volume":"39","author":"IA Paschou","year":"2025","unstructured":"Paschou IA, Sali E, Paschou SA, Psaltopoulou T, Nicolaidou E, Stratigos AJ. The effects of GLP-1RA on inflammatory skin diseases: a comprehensive review. J Eur Acad Dermatol Venereol. 2025;39(12):2047\u201355. https:\/\/doi.org\/10.1111\/jdv.20694.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"1049_CR3","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1093\/ced\/llad182","volume":"48","author":"D Mintoff","year":"2023","unstructured":"Mintoff D, Agius R, Benhadou F, Das A, Frew JW, Pace NP. Obesity and hidradenitis suppurativa: targeting meta-inflammation for therapeutic gain. Clin Exp Dermatol. 2023;48(9):984\u201390. https:\/\/doi.org\/10.1093\/ced\/llad182.","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"1049_CR4","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1177\/12034754241285592","volume":"28","author":"R Khalaf","year":"2024","unstructured":"Khalaf R, Davalan W, AlHusayen R. Effectiveness of weight loss drugs in the management of hidradenitis suppurativa: a systematic review. J Cutan Med Surg. 2024;28(6):614\u20135. https:\/\/doi.org\/10.1177\/12034754241285592.","journal-title":"J Cutan Med Surg"},{"issue":"6","key":"1049_CR5","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/bjd.19435","volume":"183","author":"JR Ingram","year":"2020","unstructured":"Ingram JR. The epidemiology of hidradenitis suppurativa. Br J Dermatol. 2020;183(6):990\u20138. https:\/\/doi.org\/10.1111\/bjd.19435.","journal-title":"Br J Dermatol"},{"issue":"12","key":"1049_CR6","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1111\/ijd.16892","volume":"62","author":"T Henry","year":"2023","unstructured":"Henry T, et al. Therapeutic potential of GLP-1 agonists for hidradenitis suppurativa. Int J Dermatol. 2023;62(12):1543\u20134. https:\/\/doi.org\/10.1111\/ijd.16892.","journal-title":"Int J Dermatol"},{"issue":"1","key":"1049_CR7","doi-asserted-by":"publisher","first-page":"T56","DOI":"10.1016\/j.ad.2023.10.019","volume":"115","author":"E Vilarrasa","year":"2024","unstructured":"Vilarrasa E, et al. Glucagon-like peptide-1 agonists for treating obesity in patients with immune-mediated skin diseases. Actas Dermosifiliogr. 2024;115(1):T56\u201365. https:\/\/doi.org\/10.1016\/j.ad.2023.10.019.","journal-title":"Actas Dermosifiliogr"},{"issue":"5","key":"1049_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3390\/diseases13050127","volume":"13","author":"C Persson","year":"2025","unstructured":"Persson C, Eaton A, Mayrovitz HN. A closer look at the dermatological profile of GLP-1 agonists. Diseases. 2025;13(5):127. https:\/\/doi.org\/10.3390\/diseases13050127.","journal-title":"Diseases"},{"issue":"4 Suppl","key":"1049_CR9","doi-asserted-by":"publisher","first-page":"AB89","DOI":"10.1016\/j.jaad.2012.12.370","volume":"68","author":"E Javorsky","year":"2013","unstructured":"Javorsky E. Hidradenitis suppurativa: patient experiences with bariatric surgery. J Am Acad Dermatol. 2013;68(4 Suppl):AB89. https:\/\/doi.org\/10.1016\/j.jaad.2012.12.370.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1049_CR10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1177\/1203475419874412","volume":"24","author":"A Sivanand","year":"2020","unstructured":"Sivanand A, Gulliver WP, Josan CK, Alhusayen R, Fleming PJ. Weight loss and dietary interventions for hidradenitis suppurativa: a systematic review. J Cutan Med Surg. 2020;24(1):64\u201372. https:\/\/doi.org\/10.1177\/1203475419874412.","journal-title":"J Cutan Med Surg"},{"issue":"5","key":"1049_CR11","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jdcr.2017.06.008","volume":"3","author":"C Gallagher","year":"2017","unstructured":"Gallagher C, Kirthi S, Burke T, O\u2019Shea D, Tobin AM. Remission of hidradenitis suppurativa after bariatric surgery. JAAD Case Rep. 2017;3(5):436. https:\/\/doi.org\/10.1016\/j.jdcr.2017.06.008.","journal-title":"JAAD Case Rep."},{"key":"1049_CR12","unstructured":"Lal K, Herringshaw E. The use of GLP-1 agonists in the management of cutaneous disease. J Clin Aesthet Dermatol. 2024;17(9):34. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11386968\/."},{"issue":"17","key":"1049_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2024.100679","volume":"18","author":"FB Rivera","year":"2024","unstructured":"Rivera FB, et al. Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials. Am J Prev Cardiol. 2024;18(17):100679. https:\/\/doi.org\/10.1016\/j.ajpc.2024.100679.","journal-title":"Am J Prev Cardiol."},{"issue":"10","key":"1049_CR14","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653\u201362. https:\/\/doi.org\/10.1016\/S2213-8587(21)00203-5.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"1049_CR15","first-page":"422","volume":"24","author":"A Parvathaneni","year":"2025","unstructured":"Parvathaneni A, et al. Exploring the therapeutic potential of GLP-1 agonists in hidradenitis suppurativa. J Drugs Dermatol. 2025;24(4):422\u20133.","journal-title":"J Drugs Dermatol"},{"issue":"21","key":"1049_CR16","doi-asserted-by":"publisher","first-page":"6292","DOI":"10.3390\/jcm13216292","volume":"13","author":"PK Krajewski","year":"2024","unstructured":"Krajewski PK, Z\u0142otowska A, Szepietowski JC. The therapeutic potential of GLP-1 receptor agonists in the management of hidradenitis suppurativa: a systematic review of anti-inflammatory and metabolic effects. J Clin Med. 2024;13(21):6292. https:\/\/doi.org\/10.3390\/jcm13216292.","journal-title":"J Clin Med"},{"issue":"3","key":"1049_CR17","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/bjd.15742","volume":"177","author":"L Emtestam","year":"2017","unstructured":"Emtestam L, Sartorius K. Glucagon-like peptide-1 agonists for treatment of hidradenitis suppurativa. Br J Dermatol. 2017;177(3):625\u20137. https:\/\/doi.org\/10.1111\/bjd.15742.","journal-title":"Br J Dermatol"},{"key":"1049_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"1049_CR19","doi-asserted-by":"publisher","first-page":"AB324","DOI":"10.1016\/j.jaad.2025.05.1277","volume":"93","author":"IN Encarnacion","year":"2025","unstructured":"Encarnacion IN, Desir N, Anusionwu I, Ogunleye T, Taylor S. 62064 The role of GLP-1 agonists in overweight and obese hidradenitis suppurativa patients: a retrospective analysis. J Am Acad Dermatol. 2025;93:AB324. https:\/\/doi.org\/10.1016\/j.jaad.2025.05.1277.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1049_CR20","doi-asserted-by":"publisher","first-page":"e662","DOI":"10.1111\/jdv.20392","volume":"39","author":"MI Posada","year":"2025","unstructured":"Posada MI, Alora MB, Lima XTV. Impact of semaglutide use in obese and diabetic patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2025;39(8):e662\u20134. https:\/\/doi.org\/10.1111\/jdv.20392.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1049_CR21","doi-asserted-by":"publisher","DOI":"10.1177\/12034754251320045","author":"MM Rames","year":"2025","unstructured":"Rames MM, Alavi A, Aghazadeh N. GLP-1 agonists in patients with hidradenitis suppurativa: a case series. J Cutan Med Surg. 2025. https:\/\/doi.org\/10.1177\/12034754251320045.","journal-title":"J Cutan Med Surg"},{"issue":"3","key":"1049_CR22","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.medcli.2023.11.007","volume":"162","author":"J Nicolau","year":"2024","unstructured":"Nicolau J, et al. Liraglutide for the treatment of obesity among patients with hidradenitis suppurativa. Med Clin (Barc). 2024;162(3):118\u201322. https:\/\/doi.org\/10.1016\/j.medcli.2023.11.007.","journal-title":"Med Clin (Barc)"},{"key":"1049_CR23","doi-asserted-by":"publisher","first-page":"AB89","DOI":"10.1016\/j.jaad.2023.07.359","volume":"89","author":"C Drumm","year":"2023","unstructured":"Drumm C, et al. 42762 Successful treatment of hidradenitis suppurativa with semaglutide. J Am Acad Dermatol. 2023;89:AB89. https:\/\/doi.org\/10.1016\/j.jaad.2023.07.359.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1049_CR24","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1111\/BJD.15233","volume":"177","author":"L Jennings","year":"2017","unstructured":"Jennings L, et al. The treatment of hidradenitis suppurativa with the glucagon-like peptide-1 agonist liraglutide. Br J Dermatol. 2017;177(3):858\u20139. https:\/\/doi.org\/10.1111\/BJD.15233.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1049_CR25","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1159\/000473873","volume":"9","author":"BN Khandalavala","year":"2017","unstructured":"Khandalavala BN. A disease-modifying approach for advanced hidradenitis suppurativa (regimen with metformin, liraglutide, dapsone, and finasteride): a case report. Case Rep Dermatol. 2017;9(2):70\u20138. https:\/\/doi.org\/10.1159\/000473873.","journal-title":"Case Rep Dermatol"},{"issue":"10","key":"1049_CR26","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1001\/jamadermatol.2025.2723","volume":"161","author":"L Gouvrion","year":"2025","unstructured":"Gouvrion L, Delage M, Villani AP, et al. Glucagon-like peptide-1 receptor agonists in hidradenitis suppurativa. JAMA Dermatol. 2025;161(10):1084\u20136. https:\/\/doi.org\/10.1001\/jamadermatol.2025.2723.","journal-title":"JAMA Dermatol"},{"key":"1049_CR27","doi-asserted-by":"publisher","first-page":"AB88","DOI":"10.1016\/j.jaad.2025.05.356","volume":"93","author":"S Romanelli","year":"2025","unstructured":"Romanelli S, et al. 62918 The effect of glucagon-like peptide (GLP)-1 agonists on hidradenitis suppurativa disease severity and musculoskeletal symptoms: a Quality Improvement Initiative by International Dermatology Outcome Measures (IDEOM). J Am Acad Dermatol. 2025;93:AB88. https:\/\/doi.org\/10.1016\/j.jaad.2025.05.356.","journal-title":"J Am Acad Dermatol"},{"key":"1049_CR28","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jdcr.2024.02.023","volume":"52","author":"LJ Chan","year":"2024","unstructured":"Chan LJ, Kaur M, Kaffenberger BH. A case of recalcitrant hidradenitis suppurativa concomitantly treated with tirzepatide. JAAD Case Rep. 2024;52:101\u20132. https:\/\/doi.org\/10.1016\/j.jdcr.2024.02.023.","journal-title":"JAAD Case Rep."},{"key":"1049_CR29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jdin.2025.05.004","volume":"21","author":"R Gupta","year":"2025","unstructured":"Gupta R, et al. Patient-reported outcomes of glucagon-like peptide-1 agonists on hidradenitis suppurativa severity\u2019. JAAD Int. 2025;21:40\u20133. https:\/\/doi.org\/10.1016\/j.jdin.2025.05.004.","journal-title":"JAAD Int"},{"issue":"4","key":"1049_CR30","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1093\/bjd\/ljae216","volume":"191","author":"D Lyons","year":"2024","unstructured":"Lyons D, et al. Semaglutide for weight loss in people with obesity as an adjunctive treatment for hidradenitis suppurativa: its impact on disease control and quality of life. Br J Dermatol. 2024;191(4):631\u20133. https:\/\/doi.org\/10.1093\/bjd\/ljae216.","journal-title":"Br J Dermatol"},{"key":"1049_CR31","unstructured":"Salem Y, et al. GLP-1 medications are associated with improved outcomes in hidradenitis suppurativa. Gulf Coast Division GME Research Day. 2025 [Conference abstract]. Available from: https:\/\/scholarlycommons.hcahealthcare.com\/gulfcoast2025\/76"},{"key":"1049_CR32","doi-asserted-by":"publisher","first-page":"AB81","DOI":"10.1016\/j.jaad.2025.05.329","volume":"93","author":"M Hill","year":"2025","unstructured":"Hill M, Bordeaux J. 60888 Semaglutide weight loss effects on hidradenitis suppurativa severity. J Am Acad Dermatol. 2025;93:AB81. https:\/\/doi.org\/10.1016\/j.jaad.2025.05.329.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1049_CR33","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jaad.2024.11.039","volume":"92","author":"MA Hill","year":"2025","unstructured":"Hill MA, Bordeaux JS. Semaglutide use for decreasing hidradenitis suppurativa resource utilization: a retrospective cohort study utilizing TriNetX. J Am Acad Dermatol. 2025;92(4):896\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2024.11.039.","journal-title":"J Am Acad Dermatol"},{"key":"1049_CR34","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/ijd.17910","volume":"65","author":"RK Islam","year":"2026","unstructured":"Islam RK, et al. A-MACE-ing: a real-world analysis of semaglutide\u2019s impact on major adverse cardiovascular events (MACE) in patients with hidradenitis suppurativa. Int J Dermatol. 2026;65:365\u20136. https:\/\/doi.org\/10.1111\/ijd.17910.","journal-title":"Int J Dermatol"},{"issue":"8 Suppl","key":"1049_CR35","doi-asserted-by":"publisher","first-page":"S185","DOI":"10.1016\/j.jid.2025.06.1335","volume":"145","author":"EJ Ma","year":"2025","unstructured":"Ma EJ, et al. LB1062 The impact of GLP-1 receptor agonists on major adverse cardiovascular events among hidradenitis suppurativa, psoriasis, and atopic dermatitis patients: a population-based cohort study. J Invest Dermatol. 2025;145(8 Suppl):S185. https:\/\/doi.org\/10.1016\/j.jid.2025.06.1335.","journal-title":"J Invest Dermatol"},{"issue":"12","key":"1049_CR36","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/S0735-1097(25)00996-9","volume":"85","author":"J Choi","year":"2025","unstructured":"Choi J, Vera AO, Olexson M, Ro C, Enos C. Increased incidence of major adverse cardiovascular events in patients with type II diabetes and hidradenitis suppurativa despite GLP-1RA therapy. J Am Coll Cardiol. 2025;85(12):512. https:\/\/doi.org\/10.1016\/S0735-1097(25)00996-9.","journal-title":"J Am Coll Cardiol"},{"key":"1049_CR37","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljaf085.149","author":"L Killion","year":"2025","unstructured":"Killion L, Hughes R, Kirby B. P121 Treatment with semaglutide improves the systemic inflammatory burden associated with hidradenitis suppurativa. Br J Dermatol. 2025. https:\/\/doi.org\/10.1093\/bjd\/ljaf085.149.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1049_CR38","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1080\/09546634.2021.1882658","volume":"33","author":"G Chang","year":"2022","unstructured":"Chang G, Chen B, Zhang L. Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type 2 diabetes: a systematic review and meta-analysis of prospective cohort and before-after studies. J Dermatolog Treat. 2022;33(3):1299\u2013305. https:\/\/doi.org\/10.1080\/09546634.2021.1882658.","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"1049_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13377","volume":"51","author":"CC Chi","year":"2021","unstructured":"Chi CC, Lee CY, Liu CY, Wang SH, Tien O\u2019Donnell F, Tung TH. Effects of antidiabetic drugs on psoriasis: a meta-analysis. Eur J Clin Invest. 2021;51(2):e13377. https:\/\/doi.org\/10.1111\/eci.13377.","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"1049_CR40","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/RHU.0000000000001949","volume":"30","author":"D Karacabeyli","year":"2024","unstructured":"Karacabeyli D, Lacaille D. Glucagon-like peptide-1 receptor agonists in patients with inflammatory arthritis or psoriasis: a scoping review. J Clin Rheumatol. 2024;30(1):26\u201331. https:\/\/doi.org\/10.1097\/RHU.0000000000001949.","journal-title":"J Clin Rheumatol"},{"key":"1049_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/ajd.70125","volume":"0","author":"H Bhullar","year":"2026","unstructured":"Bhullar H, Veysey E, Bohl T, Prakash S, Smithson S. Complete skin remission of lichen planus with tirzepatide. Australas J Dermatol. 2026;0:1\u20132. https:\/\/doi.org\/10.1111\/ajd.70125.","journal-title":"Australas J Dermatol"},{"key":"1049_CR42","doi-asserted-by":"publisher","DOI":"10.1177\/20420188231222367","volume":"15","author":"SH Alharbi","year":"2024","unstructured":"Alharbi SH. Anti-inflammatory role of glucagon-like peptide-1 receptor agonists and its clinical implications. Ther Adv Endocrinol Metab. 2024;15:20420188231222367. https:\/\/doi.org\/10.1177\/20420188231222367.","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"16","key":"1049_CR43","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.3390\/cells11162587","volume":"11","author":"AKO Rode","year":"2022","unstructured":"Rode AKO, et al. Induced human regulatory T cells express the glucagon-like peptide-1 receptor. Cells. 2022;11(16):2542\u201387. https:\/\/doi.org\/10.3390\/cells11162587.","journal-title":"Cells"},{"issue":"7","key":"1049_CR44","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1080\/09546634.2019.1708853","volume":"32","author":"P Chen","year":"2021","unstructured":"Chen P, et al. Liraglutide improved inflammation via mediating IL-23\/Th-17 pathway in obese diabetic mice with psoriasiform skin. J Dermatolog Treat. 2021;32(7):745\u201351. https:\/\/doi.org\/10.1080\/09546634.2019.1708853.","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"1049_CR45","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/exd.12081","volume":"22","author":"A Faurschou","year":"2013","unstructured":"Faurschou A, et al. Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques. Exp Dermatol. 2013;22(2):150\u20132. https:\/\/doi.org\/10.1111\/exd.12081.","journal-title":"Exp Dermatol"},{"issue":"2","key":"1049_CR46","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1177\/2042018814543483","volume":"5","author":"MR Al-Badri","year":"2014","unstructured":"Al-Badri MR, Azar ST. Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis. Ther Adv Endocrinol Metab. 2014;5(2):34\u20138. https:\/\/doi.org\/10.1177\/2042018814543483.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"1049_CR47","doi-asserted-by":"publisher","first-page":"603281","DOI":"10.3389\/fmed.2021.603281","volume":"8","author":"JW Frew","year":"2021","unstructured":"Frew JW, Singh N, Jiang CS, Vaughan R, Krueger JG. The impact of body mass index upon the efficacy of adalimumab in hidradenitis suppurativa. Front Med. 2021;8:603281. https:\/\/doi.org\/10.3389\/fmed.2021.603281.","journal-title":"Front Med"},{"issue":"6","key":"1049_CR48","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/ijd.16565","volume":"62","author":"A Nosrati","year":"2023","unstructured":"Nosrati A, et al. Adalimumab efficacy is inversely correlated with body mass index (BMI) in hidradenitis suppurativa. Int J Dermatol. 2023;62(6):764\u20139. https:\/\/doi.org\/10.1111\/ijd.16565.","journal-title":"Int J Dermatol"},{"issue":"2","key":"1049_CR49","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s13555-022-00872-1","volume":"13","author":"A Garg","year":"2023","unstructured":"Garg A, et al. Real-world findings on the characteristics and treatment exposures of patients with hidradenitis suppurativa from US claims data. Dermatol Ther. 2023;13(2):581\u201394. https:\/\/doi.org\/10.1007\/s13555-022-00872-1.","journal-title":"Dermatol Ther"},{"issue":"6","key":"1049_CR50","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s40257-023-00796-2","volume":"24","author":"A Garg","year":"2023","unstructured":"Garg A, et al. Disease burden and treatment patterns among US patients with hidradenitis suppurativa: a retrospective cohort study. Am J Clin Dermatol. 2023;24(6):977\u201390. https:\/\/doi.org\/10.1007\/s40257-023-00796-2.","journal-title":"Am J Clin Dermatol"},{"key":"1049_CR51","doi-asserted-by":"publisher","first-page":"1321782","DOI":"10.1155\/2020\/1321782","volume":"2020","author":"N Skroza","year":"2020","unstructured":"Skroza N, et al. Evaluation of cardiovascular risk in hidradenitis suppurativa patients using heart rate variability (HRV) analysis. Cardiovasc Ther. 2020;2020:1321782. https:\/\/doi.org\/10.1155\/2020\/1321782.","journal-title":"Cardiovasc Ther"},{"issue":"4","key":"1049_CR52","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3390\/jcm14041110","volume":"14","author":"TZ Rohan","year":"2025","unstructured":"Rohan TZ, Hafer R, Duong T, Dasgupta R, Yang S. Hidradenitis suppurativa is associated with an increased risk of adverse cardiac events and all-cause mortality. J Clin Med. 2025;14(4):1110. https:\/\/doi.org\/10.3390\/jcm14041110.","journal-title":"J Clin Med"},{"issue":"4","key":"1049_CR53","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1001\/jamadermatol.2015.6264","volume":"152","author":"A Egeberg","year":"2016","unstructured":"Egeberg A, Gislason GH, Hansen PR. Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa. JAMA Dermatol. 2016;152(4):429\u201334. https:\/\/doi.org\/10.1001\/jamadermatol.2015.6264.","journal-title":"JAMA Dermatol"},{"issue":"11","key":"1049_CR54","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.3390\/biomedicines10112973","volume":"10","author":"E Rosi","year":"2022","unstructured":"Rosi E, et al. Hidradenitis suppurativa: the influence of gender, the importance of trigger factors and the implications for patient habits. Biomedicines. 2022;10(11):2973. https:\/\/doi.org\/10.3390\/biomedicines10112973.","journal-title":"Biomedicines."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01049-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-026-01049-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-026-01049-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:32:13Z","timestamp":1789464733000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-026-01049-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1049"],"URL":"https:\/\/doi.org\/10.1007\/s40257-026-01049-8","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"18 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors did not receive support from any organization for the submitted work.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M-A.V has acted as a sub-investigator in clinical trials for Abbvie. EC has acted as a sub-investigator in clinical trials for Abbvie. EP has acted as a sub-investigator in clinical trials for Abbvie, MoonLake Immunotherapeutics and UCB, received honoraria from Johnson and Johnson and UCB and participated in advisory boards for UCB. CC has received honoraria from Sanofi and Johnson & Johnson Romania. RH has received honoraria from Abbvie, Novartis, UCB. BK has received research support\/P.I. (clinical trials) from AbbVie, Almirall, Janssen, Merck Sharpe Dolme, Moonlake, Novartis, Pfizer and UCB; has been a consultant for AbbVie, Almirall, Arctic Biotech, Celgene, Janssen, Leo, MC2 therapeutics, Moonlake, Merck Sharpe Dolme, Novartis, Pfizer, UCB, Union and Zubria; received honoraria from Abbvie, Almirall, Celgene, Janssen, Lilly, MC2 therapeutics, Novartis, Pfizer, Union, and UCB; and been on scientific advisory boards for AbbVie, Almirall, Celgene, Janssen, Lilly, Novartis, Pfizer, Union and UCB. All other authors report no conflicts of interest.","order":2,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All information extracted and analyzed in this review is included within the article and its Online Resources. The complete data extraction sheet is available from the corresponding author upon reasonable request.","order":3,"name":"Ethics","label":"Availability of Data and Materials","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study is a systematic review of previously published literature and does not involve human participants or animal research.","order":4,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conceptualization: M-A.V., B.K.; Methodology: All authors; Data curation: M-A.V., with review and validation by all authors; Formal analysis: M-A.V.; Writing\u2014original draft: M-A.V.; Writing\u2014review and editing: All authors; Supervision: B.K. All authors read and approved the final manuscript.","order":8,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}